Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Scott

Showing results (301-310 of 338) with videos related to

Pageof 34
Sort By:
F1000Research|April 30, 2016
Innovations and best practice in undergraduate educationGeorge R Littlejohn, Graham Scott, Mary Williams
Journal of Clinical Pharmacology|November 12, 2013
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazarFrances Stringer, Joost DeJongh, Graham Scott, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|April 28, 2007
Hallucinations in adolescents with post-traumatic stress disorder and psychotic disorderJames Graham Scott, Barry Nurcombe, Judith Sheridan, et al.
Dermatology (Basel, Switzerland)|July 2, 2003
Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open studyDiamant Thaçi, Katrin Steinmeyer, Marie-Eve Ebelin, et al.
European Journal of Clinical Pharmacology|September 11, 2012
The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agentFrances Stringer, Graham Scott, Marian Valbuena, et al.
Journal of Clinical Pharmacology|January 30, 2004
Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjectsGraham Scott, Linda Yih, Ching-Ming Yeh, et al.
Clinical Pharmacokinetics|April 15, 2004
Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxibGraham Scott, Christine Vinluan Reynolds, Slavica Milosavljev, et al.
The Journal of Dermatological Treatment|August 13, 2005
A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitisMark Ling, Alice Gottlieb, David Pariser, et al.
European Heart Journal. Cardiovascular Imaging|August 22, 2022
Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art reviewReece Parry, Kamran Majeed, Fiona Pixley, et al.
British Journal of Clinical Pharmacology|February 8, 2019
Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelinNelleke Snelder, Henk-Jan Drenth, Kirsten Riber Bergmann, et al.
Pageof 34

Showing results (301-310 of 338) with videos related to

Sort By:
Pageof 34
F1000Research|April 30, 2016
Innovations and best practice in undergraduate educationGeorge R Littlejohn, Graham Scott, Mary Williams
Journal of Clinical Pharmacology|November 12, 2013
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazarFrances Stringer, Joost DeJongh, Graham Scott, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|April 28, 2007
Hallucinations in adolescents with post-traumatic stress disorder and psychotic disorderJames Graham Scott, Barry Nurcombe, Judith Sheridan, et al.
Dermatology (Basel, Switzerland)|July 2, 2003
Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open studyDiamant Thaçi, Katrin Steinmeyer, Marie-Eve Ebelin, et al.
European Journal of Clinical Pharmacology|September 11, 2012
The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agentFrances Stringer, Graham Scott, Marian Valbuena, et al.
Journal of Clinical Pharmacology|January 30, 2004
Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjectsGraham Scott, Linda Yih, Ching-Ming Yeh, et al.
Clinical Pharmacokinetics|April 15, 2004
Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxibGraham Scott, Christine Vinluan Reynolds, Slavica Milosavljev, et al.
The Journal of Dermatological Treatment|August 13, 2005
A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitisMark Ling, Alice Gottlieb, David Pariser, et al.
European Heart Journal. Cardiovascular Imaging|August 22, 2022
Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art reviewReece Parry, Kamran Majeed, Fiona Pixley, et al.
British Journal of Clinical Pharmacology|February 8, 2019
Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelinNelleke Snelder, Henk-Jan Drenth, Kirsten Riber Bergmann, et al.
Pageof 34